Psych CASC / OSCE · Psychopharmacology — lithium
Explaining lithium monitoring and suicide benefit to a patient (CASC)
CASC-style communication station: shared decision on lithium vs valproate defaults, monitoring plan, interaction/sick-day rules, anti-suicide evidence, and balanced organ and pregnancy risk framing.
On this page
Study tools
Target exams
Station instructions (candidate)
You have 7 minutes. Explain why lithium is being offered after a manic episode and serious suicide attempt, what blood monitoring means in plain language (levels plus kidney, thyroid and calcium), how everyday medicines like ibuprofen can raise levels, and which symptoms need urgent review. Balance organ and future-pregnancy concerns against relapse prevention and anti-suicide evidence. Do not guarantee cure. Do not dismiss fears. Do not invent exact national laboratory cut-offs as universal rules — explain principles and local protocols.[1][2][3]
References5ShowHide
- [1]Geddes JR, Goodwin GM, Rendell J, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial Lancet, 2010.PMID 20092882
- [2]Cipriani A, Hawton K, Stockton S, et al. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis BMJ, 2013.PMID 23814104
- [3]McKnight RF, Adida M, Budge K, et al. Lithium toxicity profile: a systematic review and meta-analysis Lancet, 2012.PMID 22265699
- [4]Patorno E, Huybrechts KF, Bateman BT, et al. Lithium Use in Pregnancy and the Risk of Cardiac Malformations N Engl J Med, 2017.PMID 28591541
- [5]Gitlin M Lithium side effects and toxicity: prevalence and management strategies Int J Bipolar Disord, 2016.PMID 27900734